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Abstract
Nitric oxide (NO) can induce acute pain in humans and plays an important role in pain sensitization caused by inflammation
and injury in animal models. There is evidence that NO acts both in the central nervous system via a cyclic GMP pathway
and in the periphery on sensory neurons through unknown mechanisms. It has recently been suggested that TRPV1 and
TRPA1, two polymodal ion channels that sense noxious stimuli impinging on peripheral nociceptors, are activated by NO in
heterologous systems. Here, we investigate the relevance of this activation. We demonstrate that NO donors directly
activate TRPV1 and TRPA1 in isolated inside-out patch recordings. Cultured primary sensory neurons display both TRPV1-
and TRPA1-dependent responses to NO donors. BH4, an essential co-factor for NO production, causes activation of a subset
of DRG neurons as assayed by calcium imaging, and this activation is at least partly dependent on nitric oxide synthase
activity. We show that BH4-induced calcium influx is ablated in DRG neurons from TRPA1/TRPV1 double knockout mice,
suggesting that production of endogenous levels of NO can activate these ion channels. In behavioral assays, peripheral
NO-induced nociception is compromised when TRPV1 and TRPA1 are both ablated. These results provide genetic evidence
that the peripheral nociceptive action of NO is mediated by both TRPV1 and TRPA1.
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Introduction
Nitric oxide (NO) is a gaseous signaling molecule generated
from arginine and oxygen by nitric oxide synthases (NOS) [1]. NO
plays essential roles in various biological processes including
vascular signaling, immune responses, neurotransmission, and
pain sensation/sensitization [2–3]. NO signaling is carried out by
at least two separate pathways. In the first pathway, NO stimulates
soluble guanylyl cyclase (sGC) to increase cyclic guanosine
monophosphate (cGMP), which in turn modulates a variety of
downstream signaling targets [4]. In the second pathway, NO
covalently and reversibly forms adducts with free thiols of cysteine
residues within proteins and hence directly modifies protein
function [5]. Although functional significance of this S-nitrosyla-
tion has not been as well established as the NO-cGMP pathway,
accumulating evidence suggests that it is a widespread mechanism
of NO action [5–6].
NO plays essential roles in development and maintenance of
pain in response to inflammation and injury through its actions at
both peripheral and central sites [3,7]. NOS enzymes are
expressed in peripheral sensory dorsal root ganglia (DRG) and
central spinal cord neurons, and are upregulated during
inflammation and injury [8–9]. The importance of NO production
in inflammatory and neuropathic pain has been well documented
through pharmacologic and genetic approaches [10–11]. Sensiti-
zation of central spinal cord neurons by NO contributes to
hyperalgesia (increased sensitivity to painful stimuli) caused by
inflammation and injury. For example, intrathecal administration
of L-arginine (a substrate of NOS) induces hyperalgesia [12],
while intrathecal administration of NOS blockers or NO
scavengers block NMDA-induced hyperalgesia and neuropathic
pain [12–13]. The mechanism of NO action on central spinal cord
neurons in pain transmission is mainly dependent on the NO-
cGMP signaling pathway [3].
In addition to modulating central neuronal activity, NO
contributes to acute and chronic pain at the periphery [7]. For
example, intracutaneous perfusion of NO causes pain sensation in
humans [14]. Local NOS inhibition blocks chronic constriction
injury (CCI)-induced neuropathic pain [15], prostaglandin E2-
induced hyperalgesia [16] and paw edema caused by bradykinin
or Substance P injection [17–18]. Furthermore, GTP cyclohy-
drolase, the rate-limiting enzyme for BH4 (tetrahydrobiopterin)
synthesis, has been shown to regulate pain sensitivity and
persistence in the periphery via BH4, an essential cofactor for
NO production by NOS [19]. Remarkably, little is known about
the molecular mechanism of NO’s involvement in peripheral pain.
It has recently been suggested in heterologous systems that several
members of the transient receptor potential (TRP) channels,
includingtwoperipherally-expressedpolymodalnocisensorsTRPV1
and TRPA1, are activated by NO donors [20–22]. However,
thermoTRPs have proven to be promiscuous receptors, and
determining a physiological relevance of TRP channel activation
requires genetic or pharmacological evidence. Here, we investigated
iftheactivationoftheTRPionchannelsbyNOcouldunderlieNO’s
involvement in peripheral pain, mainly focusing on primary sensory
neurons and behavioral consequences of NO action.
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Nitric Oxide Donor Activates Primary DRG Neurons
NO, presumably through direct activation of nociceptors,
causes acute pain in humans [14]. We thus sought to determine
if NO activates cultured DRG neurons using compounds that
spontaneously release NO. To assay large numbers of neurons
simultaneously, we used ratiometric calcium imaging which
detects global changes in cytoplasmic calcium levels and assesses
both direct (e.g., modulation of a putative calcium-permeable NO
receptor) and indirect (e.g., release of calcium from intracellular
stores and/or downstream activation of calcium-permeable ion
channels) processes. Interestingly, we observed intracellular
calcium increase in approximately ,30% of total neurons upon
application of the NO donor SNAP (S-nitroso-N-acetylpenicilla-
mine; 3 mM) (Fig. 1A, B and Table 1). Lower concentrations of
SNAP (#1 mM) did not significantly alter calcium levels in DRG
neurons [23]. A congener of SNAP lacking the releasable NO
group (NAP: N-acetylpenicillamine; 3 mM) did not activate DRG
neurons, consistent with NO-dependent activation (Fig. 1C).
SNAP had little effect in the absence of extracellular calcium ions
(Fig. 1C), suggesting that the signal was largely due to influx of
calcium through calcium-permeable ion channels. Based on the
kinetics of SNAP-evoked activation, we defined two apparently
distinct populations of neurons activated by SNAP by setting
arbitrary thresholds: those revealing a significant increase in
intracellular calcium within one minute after SNAP application
(‘‘fast-SNAP+’’ neurons, Fig. 1A left, 1B blue), and those
exhibiting a significant increase after one minute (‘‘slow-SNAP+’’
neurons, Fig. 1A right, 1B red). Soluble guanylyl cyclase (sGC), a
well-characterized molecular target of NO which causes an
increase in intracellular cGMP in many cell types [4], is not
expressed in DRG neurons [24]. We confirmed that NO donor
activates DRG neurons in a cGMP-independent manner using
the membrane-permeable cGMP analogue pCPT-cGMP (8-(4-
Chlorophenylthio)-guanosine 39,59-cyclic monophosphate) [25]
(Fig. 1C). We next tested whether TRP channels might mediate
the NO donor-induced calcium response in DRG neurons by
determining the sensitivity of the response to the non-selective
TRP channel antagonist, ruthenium red (RR). RR almost
Figure 1. NO donor activates primary cultured DRG neurons. (A, B) Responses of primary cultured DRG neurons assessed by ratiometric
calcium imaging. Fluorescent ratios (F340/F380) of individual neurons (A) and averaged traces (B) are shown. Fast-SNAP+ neurons display significantly
increased intracellular calcium upon NO donor application within one minute (blue traces), and slow-SNAP+ neurons after one minute (red traces).
Neurons without significant increases in intracellular calcium are also shown (B, green trace). Proportions of fast- and slow-SNAP+ in (B) are shown as
percentages. DRG neurons were challenged with SNAP (3 mM) for 5 min (green bar). Capsaicin (Caps, 10 mM, red bar) was applied at the end as a
control. (C) Summary of responses of primary cultured DRG neurons assessed by ratiometric calcium imaging. Proportions of neurons activated by
SNAP (three left columns; subdivided into fast-SNAP+ (blue) and slow-SNAP+ (red) responders), and pCPT-cGMP (2 mM) and NAP (3 mM; non-NO
releasing isomer of SNAP) (two right black columns) are shown. SNAP induced intracellular calcium responses were sensitive to Ruthenium red (‘‘with
RR’’) and required extracellular calcium (‘‘0 Ca(ext)’’). Cells were exposed to RR (10 mM) and calcium depleted saline 3 min prior to and throughout
SNAP application and washed out prior to capsaicin addition. The proportion responsive to capsaicin was normal in these experiments.
doi:10.1371/journal.pone.0007596.g001
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levels when applied before application of SNAP (Fig. 1C, and
Table 1). These results suggest that NO released from SNAP
activates a subset of DRG neurons through RR-sensitive ion
channel(s).
TRPV1 and TRPA1 Are Directly Activated by NO Donors
We next sought to identify the molecular target(s) of NO donors
within DRG neurons. TRPV1 and/or TRPA1 are prime
candidate receptors, as they are expressed in nociceptors, are
blocked by RR, and are known to be sensitive to reactive
chemicals via covalent modification of cysteine residues [26–28].
Arguing against this, Hinman et al. stated that NO does not
activate TRPA1 [26]. However, activation of recombinant
TRPA1 and TRPV1 by NO donors in calcium imaging
experiments has recently been reported [20–22]. Therefore, we
re-examined if recombinant TRPV1 and/or TRPA1 could serve
as molecular sensors for NO.
SNAP at 2 mM increased intracellular calcium in Chinese
Hamster Ovary (CHO) cells expressing TRPV1 or TRPA1
(Fig. 2A). SNAP produced a concentration-dependent activation
of TRPV1 and TRPA1 in Human Embryonic Kidney
(HEK293T) cells in experiments using the fluorometric imaging
plate reader (FLIPR) (Fig. 2B, C). Due to the presence of a large
background response to .5 mM SNAP, we were unable to
obtain full concentration-response curves (but see response curve
for NOR3: (6)-(E)-Ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenea-
mide, another NO donor, below, Fig. 2E). Activation of
heterologously-expressed TRPV1 and TRPA1 by SNAP (up to
4 mM) was completely blocked by RR [23].
Table 1. NO donor activates DRG neurons via TRPV1 and TRPA1.
% SNAP SNAP fast SNAP slow Capsaicin Mustard Oil
Wildtype 33.962.9 8.761.0 25.262.9 31.560.6
Wildtype+RR* 1.260.8 0.260.2 1.060.6 12.963.3
Wildtype+BCTC* 19.261.5 1.760.9 17.562.3 37.062.0
Wildtype+AP-18* 11.961.5 10.361.6 1.560.5 18.762.6
TRPV1
2/2 0.960.3 0.060.0 0.960.3 0.060.0 26.663.0
TRPA1
2/2 7.961.0 6.961.0 1.060.2 35.062.2 0.260.2
V1
2/2 A1
2/2** 1.360.1 0.060.0 1.360.1 0.060.0 0.060.0








*Ruthenium Red (10 mM), BCTC (1 mM), or AP-18 (100 mM) were applied 3 min prior to SNAP application until SNAP washout.
**ATP (100 mM) was applied in the last of the experiment as a positive control. Approximately 20% of total DRG neurons were activated by application of ATP.
doi:10.1371/journal.pone.0007596.t001
Figure 2. NO donors induce calcium influx in cells expressing TRPV1 or TRPA1. (A) SNAP (2 mM) increases intracellular calcium (F340/F380)
in rTRPV1- and hTRPA1-expressing CHO cells (black and grey lines, respectively) but not YFP-positive mock transfected CHO cells (dashed line).
Capsaicin (1 mM), mustard oil (250 mM), or ATP (100 mM) was applied as a control (‘‘CTRL’’) for TRPV1-, TRPA1-expressing, or mock-transfected cells,
respectively. Averages of at least 30 cells are shown. (B, C) Concentration-dependence of SNAP responses in rTRPV1- (B) and hTRPA1- (C) expressing
HEK293T cells obtained by FLIPR. a.u.: arbitral unit. (D–G) Normalized concentration response curves to SNAP (D), NOR3 (E), menthol (F), and
iodoacetamide (G) of HEK293T cells transiently expressing hTRPA1 (black) and C665S hTRPA1 (grey) determined by FLIPR.
doi:10.1371/journal.pone.0007596.g002
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groups of cysteine residues via S-nitrosylation [1]. TRPA1 and
TRPV1 are both activated by electrophilic molecules through
covalent modification of cysteine residues in the N-terminus
[26–28]. We next investigated whether cysteine residues of
TRPA1 are required for NO donor-dependent activation. Three
cysteines and a lysine in the N-terminal region have been
implicated in responses to reactive chemicals [26–27]. We
therefore tested whether these residues are required for NO
activation of TRPA1. As expected, both the triple cysteine (‘‘3C’’:
C621S, C641S, C665S) and the 3C with single lysine (‘‘3CK’’and
additional K710R) TRPA1 mutants revealed decreased sensitivity
to the cysteine alkylating reagent iodoacetamide (IA) as well as
SNAP [23]. However, we found the sensitivity of these clones to
the non-reactive agonists menthol [29] and 2-APB (2-Aminoethox-
ydiphenyl borate) to be moderately (3C) or severely (3CK)
compromised [23]. In an attempt to identify TRPA1 mutants
that have specific deficits in sensitivity to reactive chemicals (NO
donors and/or IA) but not non-reactive agonists (i.e., with little/no
general defects in overall channel function), we generated the three
described individual cysteine mutants of TRPA1. Compared to
wildtype TRPA1, C665S showed markedly right-shifted responses
to two chemically distinct NO donors (SNAP and NOR3) and IA,
while displaying relatively normal responses to menthol (Fig. 2D–
G). This suggests that NO donor-evoked responses are at least
partly modulated through cysteine 665, although clearly other
residues/mechanisms are also involved. C621S showed relatively
normal responses to SNAP, while C641S showed slightly
decreased sensitivity to both NO donor and menthol, and thus
is difficult to interpret [23]. Since histidines and cysteines are
prime targets of NO [30], we also tested TRPA1 mutants with
every histidine and cysteine individually mutated [31]. However,
we found no additional residues specifically required for responses
to NO but not for non-reactive agonists [23] (see Discussion).
While TRPA1 appears to be indiscriminately activated by most
reactive chemicals, TRPV1 is less promiscuous [26–28,32]. For
TRPV1, C157 is reported to be required for allicin activation; and
C616 and C621 (in the putative pore region) are proposed to be
required for NO donor activation [20,28], (however, also see [33]).
We found that NO was still able to activate TRPV1-C157.
Furthermore, the TRPV1 mutants;C616W:C621S (double cyste-
ine mutant), C616A, and C621A each revealed normal NO
donor-induced responses when normalized to capsaicin responses
[23], contrary to the findings of Yoshida and colleagues (see
Discussion) [20]. We also tested TRPV1 mutants with mutated
histidine residues [34], but none of them showed specific deficits to
SNAP [23].
To verify our calcium imaging results, and to address whether
NO-activation is membrane delimited, we next used electrophys-
iological methods to directly determine whether SNAP could
activate recombinant TRPA1 and TRPV1. Initially we monitored
TRPV1 and TRPA1 channel activity in the cell-attached
configuration which minimally disrupts the intracellular milieu
of the cell in the absence and presence of extracellularly applied
2.5–3 mM SNAP. In accordance with calcium imaging and
FLIPR experiments, TRPA1 channel activity was significantly
enhanced 5.7-fold (p,0.0001; One sample t-test) in 84% of
patches during exposure to SNAP (Fig. 3A, C). SNAP also
increased TRPV1 activity in this configuration by 2.5-fold
(p,0.05) in 67% of patches (Fig. 3A, D). Vector transfected cells
revealed no detectable change in outward current (i.e., fold
change =1) (Fig. 3A, E). Prolonged exposure to the non-NO
releasing congener of SNAP (NAP; 3 mM) elicited no change in
TRPA1 and TRPV1 channel activity for at least twice the average
latency to observe SNAP effects (Fig. 3B; p.0.2 for TRPA1 and
p.0.7 for TRPV1). To determine whether cytoplasmic constit-
uents were required for SNAP-dependent activation, we recorded
from TRPA1 and TRPV1 in excised inside-out patches in the
absence of GTP (guanosine-59-triphosphate). Robust activation of
both TRPA1 (n=3; 8.5+/22.7 fold) and TRPV1 (n=2; 3.6 and
7.2 fold) were clearly observed in this configuration (Fig. 3F, G).
These results support the hypothesis that TRPV1 and TRPA1 are
directly activated by NO.
NO Donor Activates DRG Neurons via TRPV1 and TRPA1
Since either TRPV1 or TRPA1 could mediate NO donor-
induced calcium influx into DRG neurons, we first tested whether
specific antagonists for TRPA1 (AP-18: (Z)-4-(4-chlorophynyl)-3-
methylbut-3-en-2-oxime, [35]) and TRPV1 (BCTC: N-(4-t-
Butylphenyl)-4-(3-Chloropyridin-2-yl)tetrahydropyrazine-1(2H)-
carboxamide, [36]) could inhibit DRG activation by SNAP.
Interestingly, the slow-SNAP+ population (red bars) was specifically
anddramaticallyreducedbytheTRPA1antagonistAP-18(100 mM),
while the fast-SNAP+ population was reduced by the TRPV1
antagonist BCTC (1 mM) (Fig. 4A and Table 1). AP-18 appeared to
have little if any effect on the fast-SNAP+ population, while BCTC
had little effect on the slow-SNAP+ population. These results suggest
that TRPA1 and TRPV1 mediate slow-SNAP+ and fast-SNAP+
responses, respectively, demonstrating that native TRPV1 and
TRPA1 are each required for normal NO sensing. The slow-onset
and sustained intracellular calcium increase of NO-induced responses
have been observed for TRPA1 in calcium imaging [27,37]. Also
note that the fast-SNAP+ population (,10%) is significantly less than
capsaicin-responsive population (usually 25–50% [38]), suggesting
that SNAP only activates a subset of TRPV1-positive neurons
(presumably, those expressing high TRPV1 levels). Most fast-SNAP+
cells (73.468.6%) displayed significant increases in intracellular
calcium to capsaicin while significantly fewer (28.965.6%) slow-
SNAP+ responded to capsaicin. Also, the average magnitude of the
capsaicinresponses were 2.060.1fold(fast-SNAP+)a n d1 . 3 60.1 fold
(slow-SNAP+)( p ,0.005), consistent with slow-SNAP+ responders
having smaller capsaicin sensitivity after SNAP exposure (we did not
observe any difference in the latency of SNAP-induced activation
between slow-SNAP+ Caps+ and slow-SNAP+ Caps- cells [23]). A
number of possible explanations could account for this difference
including lower TRPV1 expression and/or enhanced tachyphylaxis
of TRPV1 in this population. It should also be noted that TRPA1-
mediated slow-SNAP+ neurons do not display fast activation,
suggesting that TRPV1 functionality is not sufficient (presumably
due to low TRPV1 levels) to be activated (at detectable levels) by
SNAP in TRPA1-positive neurons, even though TRPA1 and
TRPV1 are co-expressed [39].
To further confirm the results with specific antagonists, we
performed calcium imaging experiments on primary DRG
neurons from TRPV1- and/or TRPA1-deficient animals. As
expected, the slow-SNAP+ population was specifically compro-
mised in TRPA1
2/2 DRG neurons (Fig. 4A and Table 1).
Unexpectedly, however, both fast and slow SNAP+ populations
were virtually absent in TRPV1
2/2 DRG neurons (Fig. 4A and
Table 1), in apparent contradiction to the pharmacological study
using BCTC (Fig. 4A, Wildtype + BCTC), and to our observation
that TRPA1 is responsive to NO donors in heterologous
expression systems (Fig. 2, 3). These results could be explained if
TRPA1 functionality in TRPV1
2/2 DRG neurons is compro-
mised due to lack of constitutive TRPV1 activity. Indeed, it has
been recently reported that constitutive TRPV1 activity plays a
role in stabilizing TRPA1 expression [40]. Not surprisingly, mice
TRPs Mediate NO-Induced Pain
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NO responses (Fig. 4A).
As TRPA1 appears less functional in TRPV1
2/2 DRG
neurons, we reasoned that sensitizing TRPA1 might enable us to
observe TRPA1-dependent NO responses in TRPV1
2/2 DRG
neurons. Since PKA and PLC signaling pathways are reported to
sensitize TRPA1 responses in heterologous systems [41], we
attempted to sensitize TRPA1 in TRPV1
2/2 DRG neurons by
incubating DRG neurons with the PKA activator forskolin and
PLC activator m-3M3FBS (N-(3-Trifluoromethylphenyl)-2,4,6-
trimethylbenzenesulfonamide; [42]) prior to SNAP application.
Remarkably, after incubation with forskolin and m-3M3FBS, we
were able to observe the slow-SNAP+ population in DRG neurons
from TRPV1-deficient (TRPA1
+/2 TRPV1
2/2) animals (Fig. 4B
and Table 2). The slow-SNAP+ population was absent but the
fast-SNAP+ population was retained in TRPA1-deficient
(TRPA1
2/2 TRPV1
+/2) animals, confirming that the fast-
SNAP+ is mediated by TRPV1 (Fig. 4B and Table 2). Almost-
complete reduction in SNAP+ neurons in TRPV1/A1-double
deficient animals (TRPA1
2/2 TRPV1
2/2) suggest that these two
ion channels account for calcium influx induced by SNAP, which
is the main conclusion from these studies (Fig. 4).
Figure 3. NO donor directly activates TRPV1 and TRPA1. SNAP (3 mM) increases TRP channel activity in cell-attached (A–E) and excised inside
out patches (F, G). (A, B) The average fold change induced by SNAP (3 mM) (A) or by the inactive congener NAP (3 mM) (B) in cell-attached patches
expressing TRPA1 (n=11 for (A), n=4 for (B)), rTRPV1 (n=4 for (A), n=3 for (B)) and endogenous channels from YFP-positive vector transfected cells
(‘‘Vector only’’; n=3) is shown. Quantification of SNAP induced currents involved taking the difference between the averaged current obtained at a
single voltage for all traces before and during SNAP application and the basal current level determined by averaging blank sweeps containing no TRP
activity) during these same periods. The fold increase in current induced by SNAP is the leak subtracted SNAP-induced current normalized to the leak
subtracted control current prior to SNAP addition (see Materials and Methods for more detail). (C) A cell-attached patch containing at least five
hTRPA1 channels was challenged with a step depolarization from the resting membrane potential (near 0 mV) (Vpipette from +50 to 2100 mV). Cell
was exposed to SNAP (3 mM) beginning at the arrow (green traces);latency was 40 sec. (D) A cell-attached patch containing at least three rTRPV1
channels was challenged with a voltage ramp from 2120 to +180 mV (Vpipette from +120 to 2180 mV) over 300 msec to visualize voltage-gated
channel activity. Cell was exposed to NAP (3 mM, grey sweeps) initially and then SNAP (3 mM, green) at the time indicated by the green arrow. (E) A
YFP-positive HEK293T cell expressing vector was challenged. No TRP-like SNAP-induced channel activity was observed over 2 min. Cartoon of
experimental protocol is shown. (F, G) SNAP (3 mM) activated hTRPA1 (F) and rTRPV1 (G) in excised inside out patches. Cartoon of experimental
protocol is shown. The inset in (G) shows currents in the boxed area at higher gain to indicate that the activity is consistent with the gating of at least
6 single channels. n.s. not significant.
doi:10.1371/journal.pone.0007596.g003
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One criticism of the above experiments is that we are using high
levels of NO donors, and that these levels are not physiologically
relevant (also see Discussion). We therefore investigated whether
TRPV1 and TRPA1 can be activated by endogenously-produced
NO. BH4 (tetrahydrobiopterin), an essential cofactor for NO
production by NOS, is known to increase intracellular calcium in
DRG neurons at least partly in a Nitric Oxide Synthase (NOS)-
dependent manner [19]. We observed that ,15% of total DRG
neurons displayed an increase in intracellular calcium upon BH4
(1 mM) application, and that L-NAME (Nv-Nitro-L-arginine
methyl ester hydrochloride) but not its inactive isomer D-NAME
(Nv-Nitro-D-arginine methyl ester hydrochloride) blocked the
BH4-inducedintracellular calciumincreases(Fig. 5AandTable3)
as shown previously [19]. Importantly, the increase in intracel-
lular calcium by BH4 is essentially absent in TRPV1
2/2
TRPA1
2/2 DRG neurons (Fig. 5B and Table 3), whereas
BH4-induced production of NO levels were comparable between
two genotypes as determined by the NO-sensitive fluorescence
dye DAF-FM (4-amino-5-methylamino-29,79-difluorofluorescein)
(Fig. 5C). The most straightforward conclusion from these studies
showing the specific NOS inhibitor blocks BH4-mediated calcium
increase is that TRPV1 and TRPA1 can be activated by
endogenously-generated NO. However, it cannot be excluded
t h a tB H 4 ’ sa c t i o no no t h e rp a t h w a y sm i g h tp l a yar o l ei n
increasing calcium levels.
NO Donors Cause Pain via TRPV1 and TRPA1 In Vivo
We next investigated whether peripheral nociceptive actions of
NO require TRPV1 and TRPA1. Intraplantar injection of NO
donors (SNAP at 25 mM, NOR3 at 1.5 mM, NOC7: 3-(2-
Hydroxy-1-methyl-2-nitrosohydrazino)-N-methyl-1-propanamine
at 25 mM, or glyceryl trinitrate at 0.5 mg/ml) did not evoke
significant acute pain behavior compared to vehicle responses
[23]. However, intraplantar injection of SNAP (25 mM) induced
thermal (but not mechanical) hyperalgesia in wildtype mice
(Figure 6A, leftmost set of bars). TRPV1 is known to be required
Figure 4. NO donor activates DRG neurons via TRPV1 and TRPA1. Proportion (%) of neurons activated by SNAP (3 mM) is shown and





treatments. (A) DRG neurons were challenged with SNAP (3 mM) for 5 min, followed by capsaicin (Caps, 10 mM), mustard oil (MO, 0.5 mM), and/or
ATP (100 mM) as controls (n$4 each, see Table 1 for quantitation). AP-18 (100 mM) and BCTC (1 mM) were applied 3 min prior to SNAP application. (B)
DRG neurons were first pretreated with forskolin (100 mM) and m-3M3FBS (50 mM) for 10 min, followed by the same protocol as (A). (n$7 each, see
Table 2 for quantitation). Haploinsufficiency has been reported for TRPA1 [58–59] when monitoring certain phenotypes and may influence the
proportion of slow-SNAP+ neurons observed in our cultures.
doi:10.1371/journal.pone.0007596.g004
Table 2. PKA and PLC pathways sensitize TRPA1 to NO donor.
% SNAP SNAP fast SNAP slow Capsaicin Mustard Oil
V1
+/2 A1
+/2 26.763.6 8.761.2 18.063.8 20.162.9
V1
2/2 A1
+/2 12.162.6 1.360.3 10.862.4 0.060.0 25.763.8
V1
+/2 A1
2/2 9.061.4 7.461.4 1.560.3 17.963.0 0.160.1
V1
2/2 A1
2/2 * 2.760.8 1.760.7 1.060.2 0.060.0 0.260.1
Summary of the percent of responsive ‘‘sensitized’’ DRG neurons to SNAP (3 mM), capsaicin (10 mM), and mustard oil (0.5 mM) from mice of the indicated genotypes (V1
represents TRPV1 and A1 represents TRPA1). DRG neurons were incubated with forskolin (100 mM) and m-3M3FBS (50 mM) for 10 min prior to SNAP application.
*ATP (100 mM) was applied in the last of the experiment as a positive control. Approximately 20% of total DRG neurons were activated by application of ATP.
doi:10.1371/journal.pone.0007596.t002
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stimuli. Indeed, SNAP-induced thermal hyperalgesia was largely
TRPV1-dependent (Figure 6A).
Since acute pain was not observed after NO donor injection, we
sought a protocol that would evoke NO donor-induced nocicep-
tion after pharmacologically sensitizing nociceptors. Based on our
DRG culture experiments, we tested whether pre-activation of
PLC/PKA pathways could lead to NO donor-induced nocifensive
behavior. After injection of forskolin and m-3M3FBS together
(each at 1 mM), we observed significant nocifensive behavior upon
injection of two chemically distinct NO donors (NOC7 (Fig. 6B)
and NOR3 (Fig. 6C)) over background in wildtype animals.
Remarkably, when we tested animals lacking TRPV1 and/or
TRPA1, peripheral NO donor-induced pain behavior was
compromised only when both TRPV1 and TRPA1 were ablated
(Fig. 6B, C). This indicates that NO donor-induced nociception is
dependent on both TRPV1 and TRPA1 (in another words,
activation of either TRPV1 or TRPA1 by NO donors can cause
Figure 5. BH4 activates DRG neurons via TRPV1 and TRPA1.
Proportion (%) of neurons activated by BH4 (1 mM) is shown. (A) DRG
neurons pretreated with either L-NAME or D-NAME (200 mM, n=7 each)
were challenged with BH4 for 3 min. (B) DRG neurons from TRPA1
+/2
TRPV1
+/2 (A1+/2V1+/2) or TRPA1
2/2TRPV1
2/2 (A12/2V12/2) ani-
mals were challenged with BH4 (1 mM) for 3 min. Capsaicin (10 mM) or
ATP (100 mM) were applied at the end of the experiment as controls
(n=6 separate experiments, see Table 3 for quantitation). (C) Increases
(%) in DAF fluorescence of DRG neurons of indicated genotypes are
shown (n=3 separate experiments comparing each genotype).
doi:10.1371/journal.pone.0007596.g005











2/2 1.860.4 0.060.0 0.060.0 36.566.6
Summary of the percent of responsive DRG neurons to BH4 (1 mM), capsaicin
(10 mM), mustard oil (0.5 mM), and ATP (100 mM) with indicated treatment (D-
NAME or L-NAME, both at 200 mM), or from mice of indicated genotypes (V1
represents TRPV1 and A1 represents TRPA1).
doi:10.1371/journal.pone.0007596.t003
Figure 6. NO donors induce TRPV1-dependent thermal hyper-
algesia and nocifensive behavior upon sensitization via TRPV1
and TRPA1. (A) Normalized changes in paw withdrawal latency are
shown in response to a heat stimulus (average of three stimuli) 30 min
after SNAP injection (25 mM in PBS, 1% DMSO). Decreases in paw
withdrawal latency (%) were normalized to the value of SNAP-injected
control mice (left columns) for each grouping (the larger the
percentage, the faster the withdrawl to a heat stimulus). The first
grouping represents SNAP- or vehicle- (1% DMSO) injected C57BL6
mice. The next three groupings show SNAP-induced thermal hyperal-
gesia in littermates with genotypes shown at bottom. Latencies of





+/2). (B, C) Nocifensive
response duration (flicking, licking, and lifting injected paw) recorded
over 10 min after injection of NO donors in the hindpaw. N$10 mice
were tested (N$6 for vehicle controls). Mice were first injected with
forskolin and m-3M3FBS (1 mM each) followed by NOC7 (25 mM) (B) or
NOR3 (1.5 mM) (C) injection. Genotype of animals is indicated (A1:
TRPA1, V1: TRPV1). Vehicle-injected control mice ((B): A1
+/2 V1
+/2 +
vehicle: vehicle injection 5 min after first injection, (C):CTRL+NOR3
vehicle: vehicle injection 15 min after first injection, and CTRL+FSK/
3M3FBS vehicle: first injected with vehicle for forskolin and m-3M3FBS
followed by NOR3 injection 15 min after first injection) are also shown.
CTRL mice in (C) share the same genetic background and carry at least
one copy of wildtype TRPV1 and TRPA1; the first four columns represent
results from littermates.
doi:10.1371/journal.pone.0007596.g006
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induced nociception is ablated in the double knockout mice,
although the nocifensive response duration after vehicle injection
in control animals is not statistically different from that after NO-
donor injection in double knockout mice (Fig. 6B, C).
Discussion
Nitric Oxide Donors Activate TRPV1 and TRPA1
Our studies provide genetic and pharmacological evidence that
NO donors activate TRPV1 and TRPA1 both in heterologous
systems and in naı ¨ve DRG neurons. Previous calcium imaging
studies on heterologously expressed TRPV1 and TRPA1 revealed
NO donors evoked an increase in intracellular calcium levels
dependent on channel expression [20–22]. It is presently not
known whether the gating mechanism involves an NO-dependent
shift in the voltage dependence of activation of TRPA1 and/or
TRPV1, as demonstrated for TRPV1 and TRPM8 [43–44], and
as shown for TRPA1 with regard to menthol dependent activation
[29]. Regardless, NO appears to activate TRPV1 and TRPA1
through S-nitrosylation, which involves transfer of a nitric oxide
group to cysteine sulfhydryls on proteins [5]. Consistent with this,
we observe that C665, one of three TRPA1 cytoplasmic cysteines
involved in responding to a variety of reactive chemicals [26], is
also required for normal responsiveness to NO but not to the non-
reactive agonist menthol implying that overall channel function of
this mutation is not compromised. Although unlikely, we cannot
rule out an indirect activation mechanism of TRPA1 via NO-
induced formation of a membrane-delimited chemical or via other
NO-activated redox-sensitive proteins (presumably present in
detached patches of HEK293T, CHO, DRG cells). Furthermore,
incomplete ablation of NO or iodoacetamide responses in single or
triple TRPA1 cysteine mutations suggests that other mechanisms
(residues) are also involved in sensing cysteine-reactive chemicals.
Indeed, other amino acid residues (cysteines as well as histidines) of
TRPA1 in addition to these three cysteines have recently been
reported to be required for channel activation by zinc and
intracellular base [31,34,45]. To date, how modification of
cysteines in TRPA1 by reactive chemicals translates into channel
activation is unknown. It is especially intriguing that activation
appears to be independent of the shape of the chemical, or the
type of the chemical reaction (alkylation, disulfide formation,
Michael addition, nitrosylation, deprotonation etc.) [27]. It is
possible that such reactions cause local or global conformational
changes in the N-terminus cytoplasmic domain of TRPA1 that
ultimately leads to channel gating.
There is increasing evidence that TRPV1 is also activated by
reactive chemicals. However, while TRPA1 is promiscuous and is
activated by most reactive chemicals, only a subset of such
chemicals appears to activate TRPV1 [28,32,46]. We found that
the cytoplasmic cysteine responsible for allicin-activation of
TRPV1 is not required for NO-induced activation. Yoshida
et al. proposed a general mechanism that two conserved cysteine
residues among TRPs (including TRPV1) are required for
activation by NO [20]. This finding has recently been challenged
by Xu et al. who show that reduction of disulfide bonds between
these two residues activates TRPC channels [33]. Therefore,
whether NO targets these two pore cysteines in TRP channels is
not settled. We show here that at least for TRPV1, the two pore
cysteines are not required for activation by NO donor. It is
possible that the large number of cysteine (18 Cys per subunit) and
histidine (12 His per subunit) residues in TRPV1 cooperatively
function in NO-sensing. More mechanistic studies are required to
elucidate exactly how NO (and reactive chemicals in general)
activates TRPV1, TRPA1, and other TRP channels; however, the
focus of our study is on the genetic requirement of thermoTRPs in
peripheral NO signaling in pain (below).
TRPV1 and TRPA1 Mediate Nociception in Response to
Peripheral Nitric Oxide
A role for peripherally-acting NO in hyperalgesia is supported
by pharmacological data that NOS blockers relieve inflammatory
and neuropathic pain in rodents [10–11]. Furthermore, NO
donors cause acute moderate pain in humans, suggesting a role in
acute nociception [14]. However, the behavioral consequences of
direct peripheral application of NO donors have not been
investigated in the mouse. Our studies reveal that NO donor
injection in hindpaws causes TRPV1-dependent thermal hyper-
algesia without causing significant acute pain behavior. These data
suggest that direct comparison of human and rodent pain behavior
is untenable and may point to a difficulty in assessing moderate
pain in rodents. Note that due to solubility issues of NO donors,
we were limited to using relatively low levels of NO donors for
behavioral experiments (, ten fold the in vitro EC50). For capsaicin,
injections of capsaicin at .1000 times the in vitro EC50 are typically
used to observe acute pain behavior. Therefore, it is not surprising
that significant acute nocifensive behavior was not observed, but
only hyperalgesia. Regardless, we show that after PLC and PKA
pathway activation (which sensitizes nociceptors, including
TRPV1 and TRPA1 – see below), injections of two chemically
distinct NO donors in the paw cause nociceptive behavior.
Importantly, the NO donor-dependent nocifensive behavior
required both TRPV1 and TRPA1, as we observed a decrease
in nociception in mice lacking both TRPV1 and TRPA1, but not
in individual knockout animals. This is consistent with our in vitro
results showing that NO donors can activate both ion channels,
and our DRG culture experiments, where we observe both
TRPA1- and TRPV1-mediated responses. The most parsimonious
explanation of these results is that NO’s behavioral consequences
is due to direct activation of these thermoTRPs; however, it cannot
be ruled out that NO also targets TRPV1 and TRPA1 in vivo
through indirect mechanisms. TRPV1 and TRPA1 are each well-
characterized to be required for sensing a variety of noxious
stimuli [47]; this is the first demonstration that mice lacking both
genes have a shared requirement to respond to a specific stimulus,
and therefore have overlapping functions. These two nocisensors
have overlapping expression in a subset of DRG neurons [39] and
thereby could potentially interact via intracellular signaling.
Previous studies have shown that robust activation of TRPV1
can desensitize TRPA1 [48], but also that TRPV1 is required for
proper TRPA1 expression [40]. These results point to elaborate
communications between these two nocisensors.
Potential Physiological Roles of NO-Induced TRPV1/
TRPA1 Activation
Behavioral assays involving NO performed in this study are
linked to peripheral sensitization: in one, NO donor causes
thermal sensitization (Fig. 6A); in the other, sensitization reveals a
nociceptive role for NO donors (Fig. 6B, C). Hence, the behavioral
results highlight a physiological role of peripheral NO preferen-
tially in the sensitized or hyperalgesic state. Indeed, NOS genes are
known to be expressed in DRG neurons and are upregulated
during inflammation and injury [8–9]. Moreover, macrophages,
keratinocytes, and endothelial cells are known to release NO
during inflammation, and are in close proximity to sensory nerve
endings [2,49]. Relevant to this, nitrooleic acid, an endogenous
nitrated fatty acid which is generated during excessive NO
TRPs Mediate NO-Induced Pain
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[50]. It is possible that NO and NO-derived compounds from
many cell types act together on TRPV1 and TRPA1 during
inflammation. Regardless, BH4-induced intracellular calcium
increase in primary cultured DRG neurons is partly dependent
on NOS [19], and essentially dependent on TRPV1 and TRPA1
(Fig. 5). It should be noted that we cannot exclude the possibility
that BH4 acts on other pathways to regulate neuronal activity.
Nevertheless, our results suggest that endogenous levels of NO are
capable of activating thermoTRPs, and that TRPV1 and TRPA1
are involved in NO-dependent peripheral sensitization to pain.
NO’s action on TRPV1 and TRPA1 could potentially be relevant
in other biological systems where NO and TRPV1/A1 have been
implicated to be involved. This includes the trigeminovascular
system (migraine) [51–52], synaptic plasticity in CNS [53–55], and
relaxation in the bladder [56].
Materials and Methods
Ethics Statement
All experiments involving animals were conducted with the
approval of The Scripps Research Institute Animal Research
Committee. All aspects of the program for procurement,
conditioning/quarantine, housing, management, veterinary care,
and disposal of carcasses follow the guidelines set down in the NIH
Guide for Care and Use of Laboratory Animals.
Cell Culture/Ratiometric Calcium Imaging/FLIPR
Ratiometric calcium imaging. For determination of
threshold for activation in ratiometric calcium imaging, the
magnitude of the ratio change during exposure to agonist was
normalized to the baseline ratio (fold-change) for each imaged
neuron. A histogram of the fold change of each individual neuron
in a particular experiment was constructed for each stimulus to
determine the threshold for activation. The multimodal histogram
contained one large peak around 1 (defined as the background
response) and neurons with fold-changes greater than the first
minimum (defined as threshold) were considered responsive. For
DRG neurons, at least 200 neurons were selected in each
experiment and for transiently transfected CHO cells, at least 30
YFP-positive cells were selected.
Primary DRG cultures. Extirpated thoracic and lumbar
DRGs were dissociated by incubation for one hour at 37uC
in a solution of culture medium (Ham’s F12/DMEM with 10%
Horse Serum, 1% penicillin-streptomycin) containing 0.125%
collagenase (Worthington Biochemicals) followed by a 30 min
incubation in 10 ml of culture media with 1.25 units papain.
Cells were fully dissociated with a flame-polished pipette, and
centrifuged (10 min, 1000 rpm, RT) with BSA column.
Dissociated neurons were placed on poly-D-lysine/laminin
Coated Glass Coverslips (BD Biosciences). Growth media was
supplemented with 50 ng/ml nerve growth factor and 25 ng/ml
glial cell line-derived neurotrophic factor.
Transient transfection. CHO or HEK293T cells were
transiently transfected with plasmids encoding rat TRPV1
(rTRPV1), human (hTRPA1) or mouse (mTRPA1) TRPA1, and
their mutants using FuGENE Transfection Reagent (Roche)
according to manufacturer’s instructions. CHO cells were used
for ratiometric calcium imaging experiments since they are more
adherent than HEK293T cells. HEK293T cells were used for
FLIPR because of their high transfection efficiency and for
electrophysiological experiments because they are more amenable
to performing the different patch clamp configurations used in this
study. For calcium imaging and electrophysiology, CHO or
HEK293T cells were co-transfected with a pcDNA3-based YFP
marker plasmid. Control cells were transfected with YFP vector
alone. For FLIPR experiments, HEK293T cells were transiently
transfected with plasmids using FuGENE Transfection Reagent
without co-transfecting YFP marker plasmid.
FLIPR (fluorometric imaging plate reader). For
determination of concentration-response curves by FLIPR
(Molecular Devices), HEK293T cells transiently transfected with
plasmids encoding rTRPV1, hTRPA1, or their mutants were
used. Two days after plating cells, cells were washed with assay
buffer (1X Hanks’ Balanced Salt Solution supplemented with
20 mM HEPES) and then loaded with Fluo-3 dye (Molecular
Probes) according to manufacturer’s instructions.
To enable comparison between clones at different expression
levels, all responses were normalized to the peak response to
menthol (for TRPA1) or capsaicin (for TRPV1) for the same clone
within the same experiment. Concentration response curves were
fit using Igor Pro (WaveMetrics Inc.) with a Hill equation model.
All data points represent mean 6 S.E.M.
NO Imaging
DRG neurons were loaded with DAF-FM deacetate (Invitro-
gen, 10 mM) for 20 min in the imaging buffer solution (1X Hanks’
balanced salt solution (HBSS), 10 mM HEPES). Images of DAF-
FM loaded cells with the excitation wavelength at 488 nm were
captured with a LCD camera using MetaFluor (Universal Imaging
Corp.). For direct comparison of results from different exper-
iments, the fluorescence intensity of individual cells in each
experiment was normalized to the baseline. At least 200 DRG
neurons were imaged per experiment and normalized fluorescence
intensities of individual neurons were averaged.
Electrophysiology
Cell-attached configuration of the patch clamp
technique. Cells were maintained at 25 uC in a high
extracellular K
+ saline (‘‘2 mM Ca
2+/HighK
+-ES’’) containing
(in mM): 136 KCl, 5 NaCl, 2 MgCl2, 2 CaCl2, 10 HEPES, pH 7.3
with NaOH. High extracellular K
+ was used to shift the resting
membrane potential toward 0 mV and avoid voltage dependent
changes in TRP activity due to off target effects on endogenous
background currents (the SNAP-induced conductances observed
in whole cell experiments with HEK293T cells reversed at
+1565 mV, n=3). The resting potential is likely to be close to
zero since the reversal potentials of SNAP-induced TRPV1 and
TRPA1 macroscopic or averaged currents were near zero in the
cell-attach patch configuration when voltage ramp protocols were
used. Pipettes were filled with either ‘‘0 mM Ca
2+ ES’’ or ‘‘2 mM
Ca
2+ ES’’ (which contained (in mM): 136 NaCl, 5 KCl, 2 MgCl2,
2 CaCl2, 10 HEPES, pH 7.3 with NaOH) and had resistances of
3–15 Mohm when filled. Voltage ramp- or step-induced currents
were acquired using the indicated protocols. Only patches
containing relatively few channels were chosen for study in
order to obtain blank sweeps during control and activated
conditions. All data were acquired at 11.1 KHz and single
channel records were filtered off-line at 3 KHz).
Excised inside-out configuration of the patch clamp
technique. Voltage protocols were similar to those described
for cell-attached patch experiments. Pipettes contained 2 mM
Ca
2+ ES. The bath was continuously perfused at ,26uC with a
Cs-aspartate based intracellular saline which contained (in mM):
154 L-aspartate, 5 NaCl, 5 EGTA, 0.08 CaCl2, 10 HEPES, 2
methanesulfonate, pH to 7.3 with CsOH (50 nM free Ca
2+).
Analysis of fold change in channel activity. Methods were
similar to those described in [34]. To determine the fold change in
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(sweeps containing no TRP channel openings in the absence or
presence of agonist) were used to determine the ‘‘leak’’-subtracted
control and agonist-induced level of activity at +120 mV (ramp
protocol) or +100 mV (step protocol). The fold-change in activity
was calculated by measuring the TRP-mediated current obtained
by averaging consecutive traces acquired 1 to 2 min prior to
agonist addition and during the maximal effect of agonist. Baseline
currents were stable (,5% change in basal current) throughout
the measurements.
Excised or cell-attached patch clamp data analysis. Data
in all figures and text are shown as mean 6 S.E.M. Statistical
significance of the fold change in activity was evaluated using one
sample t-test in combination with the Wilcoxon rank sum non-
parametric test.
Behavioral Assays
All experiments involving animals were conducted on littermate
male mice 6–16 weeks old with the approval of The Scripps
Research Institute Animal Research Committee. Animals were
acclimated for an about one hour in the testing environment prior
to experiments unless otherwise stated. Experimenters were blind
to genotype.
Animals. All the genetically modified animals were tested and
compared with their control (wildtype or double heterozygote)
littermates. C57BL6/J mice were used only when comparing
between wildtype animals. TRPV1
2/2 mice were obtained from
Jackson Laboratories (B6.129S4-Trpv1
tm1Jul/J) backcrossed to
C57BL6/J at least 10 generations. TRPA1
2/2 mice were on
mixed genetic background between C57BL6/J and 129/Ola
(derived from E14 ES cell) and were kindly provided by Dr. David
Corey (Harvard University).
Breeding strategy for TRPV1
2/2 TRPA1
2/2 double
deficient animals. TRPV1 and TRPA1 double knockout
animals were obtained as follows (V1:TRPV1, A1:TRPA1). First
V1
2/2 and A1

























were used for the behavioral assays.
Thermal hyperalgesia (hargreaves). Thermal
hyperalgesia assay was performed as described [57] using a
Plantar IR Analgesia Meter (Ugo Basile 7370 Plantar Test).
Baseline responses were measured one day prior to the
administration of SNAP. Responses were measured post-
injection in to the skin of left hindpaws with 10 mlo f2 5m M
SNAP or vehicle solution. Paw withdrawal latency to thermal
stimuli (three stimuli per time point) were measured and
averaged at 30 minutes post injection. 25 mM SNAP solution in
PBS was prepared right before injection by dissolving 2.5 M stock
in DMSO. Stock solution of SNAP was kept in dark.
Paw injection. NOC7: After acclimation, animals were first
injected with 10 ml of forskolin and m-3M3FBS at 1 mM each
(stock in ethanol). 5 min after the first injection, they were injected
into the same spot with 10 ml of NOC7 at 25 mM (NOC7 was
dissolved in 0.01 N NaOH, and then further dissolved into 1X
PBS and 10 mM HEPES). Time spent on pain behavior (flicking,
licking, and lifting injected paw) was recorded for 10 min after
injection of NOC7.
NOR3: After acclimation, animals were first injected with 10 ml
of forskolin and m-3M3FBS at 1 mM each (stock in DMSO).
15 min after the first injection, they were injected into the same
spot with 10 ml of NOR3 at 1.5 mM (1% DMSO as vehicle). Time
spent on pain behavior (flicking, licking, and lifting injected paw)
was recorded for 10 min after injection of NO donor.
Initially, forskolin and m-3M3FBS (‘‘sensitizers’’) dissolved as
stock solutions in DMSO were used for experiment using NOR3.
Since DMSO injection causes acute pain behavior (solution of
‘‘sensitizers’’ contained 12% DMSO, which caused ,60 sec pain
behavior over 10 min after injection), we waited 15 min until
cessation of the pain behavior. Subsequent experiments were
performed using ethanol as a vehicle for the sensitizers when it was
determined that ethanol produced no acute pain behavior. NOC7
was injected 5 min after sensitizer injection and behavior was
determined.
Site-Directed Mutagenesis
Point mutations were introduced using QuickChange Site-
Directed Mutagenesis Kit (Stratagene) according to manufactur-
er’s instructions.
Chemicals
SNAP, Fura-2, and DAF-FM were purchased from Invitrogen.
NOR3 and NOC7 were purchased from EMD Biosciences.
BCTC and AP-18 were purchased from Biomol. All the other
chemicals (capsaicin, mustard oil, forskolin, pCPT-cGMP, ruthe-
nium red, ATP, NAP, potassium chloride, L-NAME, D-NAME,
BH4, and m-3M3FBS) were purchased from Sigma-Aldrich. NO
donors and BH4 were kept in the dark and prepared immediately
before use.
Data Analysis
Error bars represents S.E.M. for all figures and tables. P-values
are based on one sample t-test in combination with the Wilcoxon
rank sum non-parametric test for electrophysiological recordings
(Fig. 3), on Student’s t-test for comparing two samples (Fig. 5, 6A),
and on one way ANOVA followed by Tukey’s honest
significance test for the remainder of experiments. * p,0.05,
** p,0.01, *** p,0.001
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